- In January 2023, Thermo Fisher Scientific Inc. completed its acquisition of The Binding Site Group, a global leader in specialty diagnostics. This strategic move, finalized from a shareholder group led by Nordic Capital, enhances Thermo Fisher's diagnostic capabilities and market presence
- In January 2023, Agilent Technologies Inc. entered an agreement with Quest Diagnostics, the top provider of diagnostic information services globally. This partnership will allow U.S. providers and patients access to the Agilent Resolution ctDx FIRST liquid biopsy NGS test, advancing cancer detection
- In December 2021, Thermo Fisher Scientific acquired PPD Inc., a company specializing in various products, including nucleotides. This acquisition aims to expand Thermo Fisher’s product portfolio and enhance its capabilities in offering comprehensive solutions in the life sciences sectors
